Headline News

 

Pall Life Sciences Commits to Innovative Technology Advances, Building Key Partnerships to Advance the Drug Production Industry in 2018

Posted on December 14, 2017

Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology

Posted on December 12, 2017

Eisai announce updated analysis of a global Phase Ib/II clinical study of its in-house anticancer agent eribulin mesylate in combination with the anti-PD-1 therapy pembrolizumab developed by Merck

Posted on December 12, 2017

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Posted on December 12, 2017

“Atezolizumab” plus “Avastin” Significantly Improves Progression Free Survival Compared with Sunitinib in PD-L1 Positive Patients for the First-line Treatment of Advanced Renal Cell Carcinoma in the IMmotion151 Study

Posted on December 12, 2017

Sartorius Stedim Biotech launches new versions of data analytics software solutions

Posted on December 07, 2017

Sanofi ends development of Clostridium difficile vaccine

Posted on December 06, 2017

Eisai submit application for its anticancer agent lenvatinib mesylate for additional indication in Taiwan

Posted on December 06, 2017

Lonza, Akouos and MEE Announce Strategic Gene Therapy License Agreements on Hearing and Balance Disorders

Posted on December 06, 2017

Lonza, Akouos and MEE Announce Strategic Gene Therapy License Agreements on Hearing and Balance Disorders

Posted on December 06, 2017

Biogen Appoints Mark Hernon as SVP, Chief Information Officer

Posted on December 06, 2017

FDA Approves Amgen’s Repatha® (evolocumab) To Prevent Heart Attack And Stroke

Posted on December 06, 2017

Vaccinex and Catalent Biologics to Collaborate on Antibody-Drug Conjugate Development

Posted on December 05, 2017

Cipla launches Q-TIB globally, a novel fixed dose combination in a single tablet for T.B. prophylaxis in HIV

Posted on December 05, 2017

TWOCELLS and Chugai Announce Performing Surgery of the First Patient in Phase III Trial for “gMSC®1,” a Regenerative Cellular Medicine for Chondrogenesis in the Knee

Posted on December 05, 2017